Loren Data's SAM Daily™

FBO DAILY - FEDBIZOPPS ISSUE OF MARCH 23, 2016 FBO #5234
MODIFICATION

A -- Preclinical Medications Discovery and Abuse Liability Testing for NIDA

Notice Date

3/21/2016
 

Notice Type

Modification/Amendment
 

NAICS

541712 — Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 3155, MSC 9593, Bethesda, Maryland, 20892, United States
 

ZIP Code

20892
 

Solicitation Number

HHS-NIH-NIDA-SBSS-17-001
 

Archive Date

4/20/2016
 

Point of Contact

Mark E. McNally, Phone: (301) 443-6677, Kenneth E Goodling, Phone: (301) 443-6677
 

E-Mail Address

mark.mcnally@nih.gov, kg25d@nih.gov
(mark.mcnally@nih.gov, kg25d@nih.gov)
 

Small Business Set-Aside

N/A
 

Description

This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; servicedisabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; womanowned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. Organizations must have in-house capability to perform in vivo rodent and primate pharmacology studies on potential pharmacotherapies for substance use disorders and on new drugs of abuse. This contract will be utilized by the Addiction Treatment Discovery Program (ATDP) within NIDA's Division of Therapeutics and Medical Consequences. Data gathered on potential pharmacotherapies will be used by the ATDP and NIDA's Medications Development Program. The data generated with new drugs of abuse will be provided to the DEA and FDA by NIDA. Testing shall include but shall not be limited to: evaluation of compounds in operant models of behavior, including responding for food reinforcement and intracranial self-stimulation, and evaluation of compounds against withdrawal from abused substances such as nicotine. Testing will also possibly include the evaluation of compounds in other animal models relevant to drug abuse and addiction, the assessment of the in vivo receptor activity of novel compounds, and the evaluation of compounds for their ability to produce, block or prevent physical dependence in rodents and/or primates. Contractors will be blinded to the identity of proprietary test compounds, and all compounds will be evaluated using protocols and experimental parameters as specified by the NIDA Project Officer. Standardized, detailed reports with graphs will be prepared and submitted promptly to the NIDA Project Officer for each compound tested. The number of compound evaluations will vary significantly from year to year. However, it is expected that 10-20 compounds per year will be evaluated in operant behavioral models in rodents and 4-6 per year compounds will be evaluated for their effects on withdrawal in rodents. It is anticipated that 2-3 compounds per year will be evaluated in other relevant animal models (e.g. assessment of in vivo receptor activity and of effects on physical dependence in rodents or primates). The successful offeror must indicate possession of current DEA registration for Schedule II-V substances prior to award and apply for appropriate Schedule I registration. The established NAICS code is 541712. Information sent should be relevant and specific in the technical area under consideration, on each of the following qualifications: 1) Experience: An outline of previous similar projects, specifically the techniques employed in the areas described above; and 2) Personnel: Name, professional qualifications and specific experience in the work requested and knowledge of, and experience in, the field of research. Any other specific and relevant information about this particular area of procurement that would improve our consideration and evaluation of the information presented is desirable. Interested organizations must demonstrate and document, in any capability statements submitted, extensive experience with and the ability to perform the above tasks. Organizations should demonstrate capability to administer and coordinate interrelated tasks in an effective and timely manner. Documentation may include, but not be limited to, contracts both Government and commercial the organization performed, references, i.e., names, titles, telephone numbers and any other information serving to document the organizations capability, e.g., awards, commendations, etc. THIS IS NOT A REQUEST FOR PROPOSALS. This notice is for information and planning purposes only and does not commit the Government to any contractual agreement. The Government does not intend to award a contract based on responses under this announcement nor otherwise pay for preparing any information sent for the Government's use. Any proprietary information should be so marked. Interested organizations presenting a capability statement must provide the following: 1) company name, address and DUNS number; 2) point of contact, 3) phone/fax/email; 4) NAICS Codes, 5) business size and status; 6) capability information in response to the requirement; and 7) type of small business your organization classifies itself as. Please submit written capability statements by April 5, 2016 to the NIDA Contracting Officer.
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/HHS-NIH-NIDA-SBSS-17-001/listing.html)
 

Place of Performance

Address: National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211 - MSC 9559, Bethesda, Maryland, 20892, United States

Zip Code: 20892
 

Record

SN04056709-W 20160323/160321235317-1b093a4bab139ee68dd89963de504924 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |